Synta Announces Elesclomol Phase 3 Melanoma Data to be Featured in Oral Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
LEXINGTON, Mass.--(BUSINESS WIRE)--May 14, 2009 - Synta Pharmaceuticals Corp. (NASDAQ: SNTA), today announced that preliminary results from the Phase 3 trial (SYMMETRYSM) of elesclomol in metastatic melanoma will be the subject of an oral presentation in the Melanoma session at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida.
Dr. Steven O'Day, Chief of Research and Director of the Melanoma Program at The Angeles Clinic and Research Institute and the North America Principal Investigator on the SYMMETRY trial will present preliminary data from the trial comparing elesclomol in combination with paclitaxel to paclitaxel alone in chemo-naïve patients with stage IV metastatic melanoma.
The oral presentation is scheduled for Saturday, May 30 from 3:30 - 3:45 p.m. ET in West Hall F3 at the Orlando Convention Center.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com.
Contact: Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125
Posted: May 2009